At a time where the world is looking to repurposed drugs to give the quickest treatment option to the COVID-19 pandemic, we interview David Fajgenbaum (University of Pennsylvania (PA, USA) and bestselling author of ‘Chasing My Cure’) on what type of treatment he considers to hold the most promise.
In this interview, Ann Van Eeckhaut (Vrije Universiteit Brussel, Belgium) discusses her current focus in metabolomics research and the challenges her research group are currently facing.
Brendan Griffin (University College Cork, Ireland) discusses his work in early drug development in this interview with Bioanalysis Zone. Brendan talks about the most common challenges faced as well as key trends in the field of developability.
In this interview, Timothy Garrett (University of Florida, FL, USA) discusses the use of MS in his research, some of the key differences between imaging MS and LC–MS and gives some top tips for method development.
Neil Spooner, Senior Editor of Bioanalysis and Founder and Director of Spooner Bioanalytical Solutions (Hertford, UK), discusses recent technological advances and current regulatory perspectives on patient-centric sampling approaches.
Michele Protti, research fellow at the University of Bologna (Italy) discusses the importance of microsampling strategies and some of the challenges faced when developing strategies with a patient-centric approach.
John Smeraglia (UCB, Brussels, Belgium) explains how translational biomarkers fit into the bioanalytical landscape and how to select an appropriate analytical methodology when carrying out translational studies.
In this interview Annette Bak, Head of Advanced Drug Delivery at AstraZeneca (Sweden), discusses her passion for engaging with the scientific community and for advocating career development for women.
In this interview Sanyogitta Puri, Associate Director (AstraZeneca, Cambridge, UK), explores AstraZeneca’s involvement in the cell and gene therapy field.
Uma Kavita (Bristol-Myers Squibb, NJ, USA) discusses lipid nanoparticle drug products and explains the importance of immunogenicity assessments as well as some of the challenges with current regulatory guidance.